Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

NCT00948389 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to meet protocol objectives

Conditions

Glioblastoma

Interventions

DRUG: Dasatinib
DRUG: Lomustine

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]